Scholar Rock is a biopharmaceutical company based in Cambridge, Massachusetts, founded in 2012. The company focuses on discovering and developing innovative therapies for serious diseases with high unmet medical needs. It was established based on significant scientific discoveries related to the molecular mechanisms of growth factor activation by its founders from Harvard Medical School and Boston Childrens Hospital.

The company specializes in a unique class of biologic therapies known as niche modulators, which selectively modulate the activation of protein growth factors, particularly from the transforming growth factor beta (TGF) superfamily. Scholar Rock's product pipeline includes investigational therapies like SRK-015 (apitegromab), a selective inhibitor of myostatin activation, which has shown promise in treating spinal muscular atrophy (SMA). The company is advancing clinical trials and preclinical programs targeting various growth factors to address additional serious diseases. Scholar Rock collaborates with academic institutions and industry partners to enhance drug discovery and development, aiming to transform the standard of care in multiple therapeutic areas.